Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients
Stock Information for Lyra Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.